MCK
OPCH
A pricey pickup
McKesson is teaming up with CD&R to acquire Option Care Health in a definitive agreement that values the home-infusion provider at roughly $5.8 billion, or $32.05 per share. That’s not pocket change — that’s “let’s write a very serious check and change the chart” money.
For McKesson, the move looks like a bid to deepen its reach in healthcare services beyond the usual distribution machine. Option Care brings a footprint in home and alternate-site infusion services, which is the kind of business that sounds niche until you remember how much healthcare is slowly drifting out of hospitals and into more convenient settings.
Why investors should care
If you own MCK, this is the kind of strategic deal that can be read two ways:
- bullish if you think McKesson is using its balance sheet to buy growth and expand its services moat
- cautious if you think $5.8 billion is a lot to pay for a business that still has to integrate cleanly and justify the price tag
For OPCH holders, the headline is simpler: there’s a cash offer on the table, and deals like this usually pull the stock toward the bid unless something weird happens in the regulatory or financing weeds.
Big picture
Healthcare distribution giants have spent years trying to look less like middlemen and more like full-stack platform companies. This deal is another reminder that in healthcare, the boring stuff is often where the real money — and the real strategy — lives.